BACKGROUND: The liver-secreted protein fetuin-A induces peripheral insulin resistance in vitro. In a pilot study, we observed that higher fetuin-A levels were associated with diabetes mellitus in older persons. However, this finding has not been confirmed in large cohorts. We sought to confirm the association of fetuin-A with incident diabetes mellitus in older persons and to determine whether the association differs by age, sex, and race and among persons with cardiovascular disease (CVD). METHODS AND RESULTS: Among 3710 community-living individuals ≥ 65 years of age without diabetes mellitus at baseline, fetuin-A was measured in serum collected in 1992 to 1993. Participants were followed up for 10.6 years (median) for incident diabetes mellitus. Cox regression models evaluated the association of fetuin-A with incident diabetes mellitus. Interaction terms evaluated heterogeneity by age, sex, race, and CVD. Mean age was 75 years; 60 were female; 15 were black; and 16 had CVD. Mean fetuin-A concentrations were 0.47 ± 0.10 g/L. During follow-up, 305 incident diabetes cases occurred. Each 0.10-g/L (SD)-greater fetuin-A was associated with 19 higher risk of diabetes mellitus (hazard ratio, 1.19; 95 confidence interval, 1.06-1.33) after adjustment for demographics, lifestyle factors, albumin, kidney function, and CVD. Further adjustment for potential mediators (body mass index, waist circumference, hypertension, lipids, and C-reactive protein) moderately attenuated the association (hazard ratio, 1.13; 95 confidence interval, 1.00-1.28). Results were similar by sex, race, and CVD status but were stronger in persons <75 years old (P for interaction=0.01). CONCLUSIONS: Higher fetuin-A is associated with incident diabetes mellitus in older persons regardless of sex, race, or prevalent CVD status. The association may be attenuated in those ≥ 75 years of age.
BACKGROUND: The liver-secreted protein fetuin-A induces peripheral insulin resistance in vitro. In a pilot study, we observed that higher fetuin-A levels were associated with diabetes mellitus in older persons. However, this finding has not been confirmed in large cohorts. We sought to confirm the association of fetuin-A with incident diabetes mellitus in older persons and to determine whether the association differs by age, sex, and race and among persons with cardiovascular disease (CVD). METHODS AND RESULTS: Among 3710 community-living individuals ≥ 65 years of age without diabetes mellitus at baseline, fetuin-A was measured in serum collected in 1992 to 1993. Participants were followed up for 10.6 years (median) for incident diabetes mellitus. Cox regression models evaluated the association of fetuin-A with incident diabetes mellitus. Interaction terms evaluated heterogeneity by age, sex, race, and CVD. Mean age was 75 years; 60 were female; 15 were black; and 16 had CVD. Mean fetuin-A concentrations were 0.47 ± 0.10 g/L. During follow-up, 305 incident diabetes cases occurred. Each 0.10-g/L (SD)-greater fetuin-A was associated with 19 higher risk of diabetes mellitus (hazard ratio, 1.19; 95 confidence interval, 1.06-1.33) after adjustment for demographics, lifestyle factors, albumin, kidney function, and CVD. Further adjustment for potential mediators (body mass index, waist circumference, hypertension, lipids, and C-reactive protein) moderately attenuated the association (hazard ratio, 1.13; 95 confidence interval, 1.00-1.28). Results were similar by sex, race, and CVD status but were stronger in persons <75 years old (P for interaction=0.01). CONCLUSIONS: Higher fetuin-A is associated with incident diabetes mellitus in older persons regardless of sex, race, or prevalent CVD status. The association may be attenuated in those ≥ 75 years of age.
Authors: G Rauth; O Pöschke; E Fink; M Eulitz; S Tippmer; M Kellerer; H U Häring; P Nawratil; M Haasemann; W Jahnen-Dechent Journal: Eur J Biochem Date: 1992-03-01
Authors: Markus Ketteler; Philipp Bongartz; Ralf Westenfeld; Joachim Ernst Wildberger; Andreas Horst Mahnken; Roland Böhm; Thomas Metzger; Christoph Wanner; Willi Jahnen-Dechent; Jürgen Floege Journal: Lancet Date: 2003-03-08 Impact factor: 79.321
Authors: Monik C Jiménez; Qi Sun; Markus Schürks; Frank B Hu; Joann E Manson; Kathryn M Rexrode Journal: Clin Chem Date: 2013-10-29 Impact factor: 8.327
Authors: Liang Yin; Wei-Juan Cai; Ling-Yun Zhu; Jun Li; Xiang-Hui Su; Xiao-Li Wang; Xiang-Yun Chang; Kan Sun Journal: Int J Clin Exp Med Date: 2015-01-15
Authors: Sarah A Aroner; Kenneth J Mukamal; David E St-Jules; Matthew J Budoff; Ronit Katz; Michael H Criqui; Matthew A Allison; Ian H de Boer; David S Siscovick; Joachim H Ix; Majken K Jensen Journal: Am J Epidemiol Date: 2016-11-17 Impact factor: 4.897
Authors: Janine Kröger; Karina Meidtner; Norbert Stefan; Marcela Guevara; Nicola D Kerrison; Eva Ardanaz; Dagfinn Aune; Heiner Boeing; Miren Dorronsoro; Courtney Dow; Guy Fagherazzi; Paul W Franks; Heinz Freisling; Marc J Gunter; José María Huerta; Rudolf Kaaks; Timothy J Key; Kay Tee Khaw; Vittorio Krogh; Tilman Kühn; Francesca Romana Mancini; Amalia Mattiello; Peter M Nilsson; Anja Olsen; Kim Overvad; Domenico Palli; J Ramón Quirós; Olov Rolandsson; Carlotta Sacerdote; Núria Sala; Elena Salamanca-Fernández; Ivonne Sluijs; Annemieke M W Spijkerman; Anne Tjonneland; Konstantinos K Tsilidis; Rosario Tumino; Yvonne T van der Schouw; Nita G Forouhi; Stephen J Sharp; Claudia Langenberg; Elio Riboli; Matthias B Schulze; Nicholas J Wareham Journal: Diabetes Date: 2018-03-09 Impact factor: 9.461